Gara Jalqabaatti › Kansarii Colorectal › North Carolina › Durham
Qorannoo klinikaalii Kansarii Colorectal Durham, NC keessatti
Qorannoo 28 Kansarii Colorectal f Durham fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
The Vanguard Study: Testing a New Way to Screen for Cancer
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · Miili 10 fagaatti
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Duke University Medical Center /ID# 279322, Durham
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Namoota walitti qabaa jiraSadarkaa 1/2
- Duke University, Durham
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- Durham VA Medical Center, Durham
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Exelixis Clinical Site #12, Durham
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Duke Cancer Center - Investigational Chemotherapy Service, Durham
- Duke Cancer Center, Durham
- Duke University Hospital - Vascular Interventional Radiology, Durham
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Namoota walitti qabaa jiraSadarkaa 1/2
- Duke Cancer Center, Durham
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
Namoota walitti qabaa jiraSadarkaa 2
- University of North Carolina Medical Center /ID# 267786, Chapel Hill · Miili 10 fagaatti
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Namoota walitti qabaa jiraSadarkaa 3
- University of North Carolina at Chapel Hill, Chapel Hill · Miili 10 fagaatti
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Namoota walitti qabaa jiraSadarkaa 3
- Duke University Medical Center, Durham
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Duke University Medical Center, Durham
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Duke University Medical Center, Durham
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- Duke University School of Medicine, Durham
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Namoota walitti qabaa jiraSadarkaa 3
- The University of North Carolina At Chapel Hill, Chapel Hill · Miili 10 fagaatti
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Namoota walitti qabaa jiraSadarkaa 3
- Duke Cancer Center, Durham
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Duke University Medical Center, Durham
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
Namoota walitti qabaa jiraSadarkaa 2
- Duke University Medical Center - Duke Cancer Center, Durham
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Duke University, Durham
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
Namoota walitti qabaa jiraSadarkaa 1/2
- GSK Investigational Site, Durham
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Duke Cancer Center, Durham
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Duke University Hospital, Durham
- Duke University Medical Center, Duke Cancer Center, Durham
- Duke University Medical Center, Durham
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
Namoota walitti qabaa jiraSadarkaa 2
- Duke University Medical Center, Durham
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
Namoota walitti qabaa jira
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill · Miili 10 fagaatti
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
Namoota walitti qabaa jiraSadarkaa 2
- Duke University Medical Center /ID# 279457, Durham
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Namoota walitti qabaa jiraSadarkaa 1
- Research Site, Durham
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Namoota walitti qabaa jiraSadarkaa 1/2
- Duke University Medical Center, Durham
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Duke Cancer Center, Durham
Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors
Namoota walitti qabaa jira
- Duke Cancer Institute, Durham
Qorannoo Kansarii Colorectal magaalota biroo keessatti
- Houston, TXQorannoo 102
- New York City, NYQorannoo 78
- Nashville, TNQorannoo 69
- Boston, MAQorannoo 63
- Los Angeles, CAQorannoo 59
- Arlington, VAQorannoo 52
- St. Louis, MOQorannoo 50
- San Antonio, TXQorannoo 46
- Philadelphia, PAQorannoo 44
- Grand Rapids, MIQorannoo 40
- Baldwin Park, CAQorannoo 37
- Chicago, ILQorannoo 34
Qorannoo biroo Durham keessatti
- Saree OljooQorannoo 64
- Saree (Gosoota Hunda)Qorannoo 58
- Kansara Qara'a Non-Small CellQorannoo 39
- Myeloma Baay’eeQorannoo 37
- Leukemia Myeloidii HamaaQorannoo 33
- Kansara MetastatikiiQorannoo 33
- Kansarii ProstateQorannoo 32
- Dhibee QaraQorannoo 32
- Kansarii OvariiQorannoo 27
- Luukemiya Limfoositiikii KeessummaaQorannoo 27
- Cufama OnneeQorannoo 26
- Kansarii PancreasQorannoo 24
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.